1. Home
  2. IOVA vs RYTM Comparison

IOVA vs RYTM Comparison

Compare IOVA & RYTM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Iovance Biotherapeutics Inc.

IOVA

Iovance Biotherapeutics Inc.

N/A

Current Price

$7.41

Market Cap

6.7B

Sector

Health Care

ML Signal

N/A

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

N/A

Current Price

$116.89

Market Cap

6.3B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
IOVA
RYTM
Founded
2007
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.7B
6.3B
IPO Year
2008
2017

Fundamental Metrics

Financial Performance
Metric
IOVA
RYTM
Price
$7.41
$116.89
Analyst Decision
Buy
Strong Buy
Analyst Count
9
19
Target Price
$14.50
★ $139.76
AVG Volume (30 Days)
★ 12.8M
1.8M
Earning Date
11-05-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
14.84
★ 28.34
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$58.86
$74.20
Revenue Next Year
$41.86
$74.91
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.08
$74.50
52 Week High
$15.37
$122.20

Technical Indicators

Market Signals
Indicator
IOVA
RYTM
Relative Strength Index (RSI) 31.10 61.81
Support Level $3.57 $82.31
Resistance Level $9.36 N/A
Average True Range (ATR) 0.57 8.19
MACD -0.13 1.40
Stochastic Oscillator 4.34 88.37

Price Performance

Historical Comparison
IOVA
RYTM

About IOVA Iovance Biotherapeutics Inc.

Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

Share on Social Networks: